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Abstract
CD8
+ T cells can exert both protective and harmful effects on the virus-infected host. However, there is no systematic
method to identify the attributes of a protective CD8
+ T cell response. Here, we combine theory and experiment to identify
and quantify the contribution of all HLA class I alleles to host protection against infection with a given pathogen. In 432
HTLV-1-infected individuals we show that individuals with HLA class I alleles that strongly bind the HTLV-1 protein HBZ had
a lower proviral load and were more likely to be asymptomatic. We also show that in general, across all HTLV-1 proteins,
CD8
+ T cell effectiveness is strongly determined by protein specificity and produce a ranked list of the proteins targeted by
the most effective CD8
+ T cell response through to the least effective CD8
+ T cell response. We conclude that CD8
+ T cells
play an important role in the control of HTLV-1 and that CD8
+ cells specific to HBZ, not the immunodominant protein Tax,
are the most effective. We suggest that HBZ plays a central role in HTLV-1 persistence. This approach is applicable to all
pathogens, even where data are sparse, to identify simultaneously the HLA Class I alleles and the epitopes responsible for a
protective CD8
+ T cell response.
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Introduction
Human T cell lymphotropic virus-type 1 (HTLV-1) is an
oncogenic retrovirus that infects between 10 and 20 million people
worldwide. Of these infected individuals, 1–6% develop adult T cell
leukaemia/lymphoma (ATL/ATLL) and a further 2 to 3% develop
a variety of chronic inflammatory syndromes including HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP);
the rest remain lifelong asymptomatic carriers (ACs) of the virus.
Most HTLV-1-infected individuals mount a large, chronically
activated CD8
+ T cell response to HTLV-1 and it is unclear why this
fails to eradicate the virus. Furthermore, there is evidence for both
protective [1–3] and pathogenic effects [4–7] of HTLV-1-specific
CD8
+ T cells. The attributes of a protective anti-HTLV-1 responsein
vivo are unknown, although specificity for the viral protein Tax is a
strong candidate. There are good reasons to believe that a Tax-
specific CD8
+ response [8] may be particularly protective. Firstly,
Tax is the immunodominant HTLV-1 antigen [9,10]. Secondly,
HLA-A*02, which is associated with protection in southern Japan
[11], binds several Tax epitopes [12], notably Tax 11–19, which is
bound unusually strongly[13]. Thirdly,Tax is one of the first HTLV-
1 proteins to be expressed and it has been shown, for HIV-1-infected
cells in vitro,t h a tC D 8
+ T cells specific to early viral proteins are
particularly effective in viral control [14]. Finally, it has been shown
that the selective pressure exerted on Tax is higher in asymptomatic
carriers than in those that have developed HAM/TSP [15].
What constitutes an effective CD8
+ T cell response is difficult to
ascertain in any infection. Measurements of CD8
+ T cell
frequency, phenotype, function and specificity are informative
but, because antigen load influences each of these factors, it can be
difficult to ascertain if a particular immune profile is the cause or
effect of good pathogen control [16–19]. An alternative approach
is host genotype analysis. Polymorphisms in immune-related
genes, particularly the HLA class I genes, have been associated
with outcome in many human infections, notably Plasmodium
falciparum, Mycobacterium tuberculosis, HIV-1, HTLV-1 and
Hepatitis B Virus infection. The benefit of a genotypic analysis is
that the direction of causality is unequivocal; the drawback is that,
in common with all ‘‘omics’’ approaches to identify biomarkers,
mechanistic insight is limited. Provided linkage disequilibrium can
be ruled out, class I associations imply that the protective effect is
mediated by CD8
+ T or NK cells. However, why one particular
allele should be protective remains unclear and so a class I
association provides no information about how to manipulate the
immune response to enhance protection.
The aim of this study was to develop a method to test the
hypothesis that the effectiveness of an individual’s HTLV-1-
specific response and thus their proviral load and HAM/TSP risk
was determined by the epitope binding properties of their HLA
class I alleles. This method resulted in the identification of the viral
protein HTLV-1 basic leucine zipper factor (HBZ) as a significant
immunogenic target for both proviral load reduction and reduced
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encoded by the complementary strand of the HTLV-1 genome
and its promoter lies in the 39 LTR rather than the 59 LTR. Our
approach is generally applicable to all pathogens, including those
in which few epitopes have been identified experimentally.
Results
Verification of epitope prediction software
Approximately 50 HLA class I-epitope pairs have been
identified for HTLV-1 [12,21–23] (mainly from the immunodo-
minant protein Tax [24] in the context of A*02); this represents a
small and non-random fraction of the ,2200 nonamer epitopes
that could be bound by the alleles of the Kagoshima cohort studied
here (Methods). Therefore we used epitope prediction software to
systematically predict HTLV-1 epitopes. The epitope prediction
software that we used has been extensively validated for a number
of other organisms including HIV-1 where it has provided useful
insight [25–31], but because of the lack of experimental data, it has
not previously been tested for HTLV-1. To validate the epitope
prediction software, we measured experimentally the binding
affinity of 200 HTLV-1 peptide-allele combinations (Table S1 in
Supporting Information S1). We found a strong positive
correlation between experimental measurement and the theoret-
ical prediction for each of the two epitope prediction methods used
namely Metaserver and Epipred (Metaserver: all P ,0.00001,
Spearman’s rank correlation; Fig. 1. Epipred: all P ,0.001,
Spearman’s rank correlation; Fig. S1 in Supporting Information
S1). We conclude that these epitope prediction software packages
Author Summary
A large immune response to the retrovirus HTLV-1 does
not always prevent HTLV-1-associated diseases. Indeed, it
has been shown that CD8
+ T cells may contribute towards
the inflammatory disease associated with HTLV-1 infection.
This observation has led to the hypothesis that it is the
‘quality’ of the immune response towards HTLV-1 that is
important, and not simply a response in itself. Using a
combination of computational and experimental methods
we have investigated T cell ‘quality’. We have found that
specificity is an important determinant of CD8
+ T cell
quality with recognition of the viral protein HBZ enabling
the host to make a more effective immune response. This
approach can be used for other pathogens to identify
what HLA class 1 alleles and the parts of the pathogen
they bind to are responsible for a protective CD8
+ T cell
immune response. This work informs basic immunology:
‘‘what constitutes a protective CD8
+ T cell response?’’;
vaccine design: ‘‘which antigens elicit the most effective
response’’ and virology: ‘‘which viral proteins are key
players in the strategy of persistence?’’.
Figure 1. The correlation between the experimentally measured binding affinities (% binding compared to control peptide) and
the predicted binding affinities (1-log (affinity)) from Metaserver of 200 HLTV-1 peptides to 4 HLA class I molecules. A*0201:
RS=0.76, P=1 610
210; B*0702: RS=0.62, P=9 610
26; A*2402: RS=0.65, P=5 610
27; B*3501: RS=0.68, P=9 610
28.
doi:10.1371/journal.ppat.1001117.g001
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binding affinities. Throughout this article figures in the main text
are obtained using Metaserver, corresponding figures from
Epipred are in Supporting Information S1. All conclusions were
replicated by both methods and by an alternative metric
(Supporting Information S1).
Protective class I alleles bind HBZ strongly
A number of associations between HLA class I alleles and
proviral load or HAM/TSP risk in HTLV-1 infection have been
identified in a population in southern Japan [3,32]. We compared
the predicted HTLV-1 peptide-binding affinities of the two
protective alleles, A*0201 and Cw*0801, with those of the known
detrimental allele, B*5401 (Methods). Peptides from the HTLV-1
protein HBZ bound to HLA-A*0201 and Cw*0801 significantly
more strongly compared to B*5401 (P=0.0002, Wilcoxon-Mann-
Whitney; Fig. 2. Repeating the analysis with another protective
allele from the A*02 family, namely A*0206 instead of A*0201
yielded identical conclusions P=0.0007, Wilcoxon-Mann-Whit-
ney, data not shown). These P values needs to be treated with
caution because the rank of the binding affinity of one HBZ
peptide for A*0201 may not be independent of the rank of the
binding affinity of a second peptide to A*0201 and similarly for
Cw*0801 and B*5401 (see Methods, independence of ranks).
However, we also found that the difference in binding strength (i.e.
the rank of the top A*0201 binding peptide minus the rank of the
top B*5401 binding peptide) was significantly greater for HBZ
than for other HTLV-1 proteins (P ,0.001, binomial test). This
statistic is based only on the top binding peptide so it does not
assume different peptides have independent binding affinity ranks.
Henceforth, we only considered the top binding peptide to avoid
the potential problem of dependence (Methods).
Asymptomatic carriers bind HBZ more strongly than
HAM/TSP patients
Having established that the known protective HLA class I
alleles code for molecules thatb i n dt op e p t i d e sf r o mH B Zm o r e
strongly than the known detrimental allele, we examined
peptide binding by all alleles in the Kagoshima cohort. We
compared the predicted epitopes for asymptomatic carriers
(n=202) and HAM/TSP patients (n=230) from the Ka-
goshima cohort. We predicted the HTLV-1 peptides bound
most strongly by each individual, given their HLA class I types
and then tested for differences between the two subject groups
(Methods). The results are shown in Table S2 in Supporting
Information S1. One result remained highly statistically
significant after correction for multiple comparisons and was
consistent across both prediction methods: asymptomatic
carriers have HLA class I alleles that bind more strongly to
peptides from HBZ compared to HAM/TSP patients (Meta-
server: P=0.0002, Wilcoxon-Mann-Whitney; Fig. 3. Epipred:
P ,0.0001, Wilcoxon-Mann-Whitney; Fig. S2 in Supporting
Information S1).
To test whether this association was caused solely by the
known protective and detrimental HLA allele families, the
analysis for HBZ was repeated excluding A*02 and B*54.T h e
results showed that, amongst the HLA-A alleles, alleles from
the A*02 family were responsible for the protective effect,
whereas in HLA-B more than one allele family contributed
significant effects. Overall, strong binding of HBZ peptides was
associated with asymptomatic status, even when A*02, B*54
and Cw*08 were excluded from the analysis (Metaserver:
P=0.04, Wilcoxon-Mann-Whitney. Epipred: P=0.006, Wil-
coxon-Mann-Whitney; Table 1).
Figure 2. The strength of binding of protective alleles (A*0201 and Cw*0801) and detrimental allele (B*5401) across the 12 HTLV-1
proteins. The y-axis gives strength of binding of the top 8 binding peptides from each protein to each of the alleles. The level of significance
indicated is corrected for multiple comparisons and provided in Table S2 in Supporting Information S1. Repeating the test with the top 5 or the top
10 instead of the top 8 peptides yielded identical conclusions.
doi:10.1371/journal.ppat.1001117.g002
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them to bind HBZ peptides strongly had a significantly
lower proviral load
Next we investigated why strong binding of HBZ peptides was
associated with remaining asymptomatic. One of the strongest
correlates of HAM/TSP is a high HTLV-1 proviral load [33]. We
therefore tested the hypothesis that strong binding of HBZ
peptides was associated with a lower proviral load. The number of
HLA class I alleles that each individual possessed that were
predicted to strongly bind peptides from HBZ was plotted against
their proviral load (Methods). We found that the number of HLA
Class I alleles that an individual had that strongly bound HBZ
peptides was significantly negatively correlated with their proviral
load (Metaserver: P=0.016, Spearman’s rank correlation; Fig. 4.
Epipred: P=0.1, Spearman’s rank correlation; Fig. S3 in
Supporting Information S1). We tested this correlation indepen-
dently in HAM/TSP patients and asymptomatic carriers and then
combined the P values (rather than simply testing the whole
cohort), so this result does not follow trivially from our previous
observation than asymptomatic carriers bind HBZ significantly
more strongly than HAM/TSP patients. An alternative metric, the
binding strength of the top HBZ-binding peptide to each allele
instead of the number of strongly binding alleles, yielded an
identical conclusion i.e. there was a significant negative correlation
between the proviral load and the strength of binding to HBZ
peptides (Metaserver: P=0.008, Spearman’s rank correlation.
Epipred: P=0.003, Spearman’s rank correlation).
HBZ peptide binding is a consistent predictor of proviral
load
Next we compared our peptide-binding analysis of HLA class I
genotype with a traditional frequency-based ‘‘presence or absence
of an allele’’ analysis. Previously a ‘‘traditional’’ analysis yielded
inconsistent results [3,32,34]. For example, A*02 was a significant
predictor of load in ACs but not in patients with HAM/TSP. We
therefore directly compared the ability of the novel peptide
binding method and the traditional genotype method to predict
proviral load in ACs and HAM/TSP patients (Table S3 in
Supporting Information S1). This analysis showed that binding
HBZ was a significant predictor of proviral load in both ACs and
HAM/TSP patients (P=0.001, P=0.017), but confirmed the
finding that in a traditional analysis HLA-A*02 (presence/absence)
was a significant predictor in ACs only (P=0.01) and HLA-B*54
for HAM/TSP patients only (P=0.019). The proportion of
variance in proviral load explained was also marginally higher for
the peptide binding analysis than the traditional analysis. The
observation that HBZ binding strength correlated with proviral
load in both ACs and HAM/TSP patients suggests that peptide
binding is the more fundamental predictor than HLA genotype.
HLA class I binding of peptides from different HTLV-1
proteins has a differential and correlated impact on both
proviral load and HAM/TSP risk
Our findings demonstrate that the HTLV-1 protein that is
associated with the most significant reduction in HAM/TSP risk
when bound by HLA class I molecules (i.e. HBZ) is also,
independently, associated with a significant reduction in proviral
load when bound. We wished to investigate whether this
relationship held across all proteins. We therefore produced two
ranked lists of proteins. In the first list we ranked the HTLV-1
proteins according to whether they were bound more strongly by
asymptomatic carriers or HAM/TSP patients (Fig. 5 x-axis; at the
extremes ACs were significantly more likely to bind peptides from
HBZ, HAM/TSP patients were significantly more likely to bind
peptides from Env). This list could be viewed as the rank order of
targets for a vaccine designed to reduce HAM/TSP risk. In the
second list we ranked the proteins according to whether binding
their peptides was associated with a lower proviral load (Fig. 5, y-
axis; at the extremes, binding of HBZ was associated with a
significantly lower proviral load, whereas binding of Env was
associated with a significantly higher proviral load). This list could
be viewed as the rank order of targets for a vaccine designed to
reduce proviral load. We then compared these two sets of ranks
and found them to be strongly positively correlated (Metaserver:
RS=0.86, P=0.0005, Spearman’s rank correlation; Fig. 5.
Epipred: RS=0.66, P=0.02, Spearman’s rank correlation; Fig.
S4 in Supporting Information S1). That is, proteins whose
peptides are bound strongly by asymptomatic carriers are,
independently, those associated with a lower proviral load when
bound. This observation has two important implications. Firstly,
HLA class I binding of peptides from different proteins has a
differential impact on both proviral load and HAM/TSP risk; i.e.
CD8
+ efficiency (ability to reduce proviral load and disease risk) is
determined by protein specificity and we have established a list of
Figure 3. The strength of binding of the HLA class I alleles of
asymptomatic carriers and HAM/TSP patients to HBZ. Asymp-
tomatic carriers have HLA class I alleles that are predicted to bind HBZ
significantly more strongly than HAM/TSP patients (P=0.0002).
doi:10.1371/journal.ppat.1001117.g003
Table 1. The difference in binding strength to HBZ between
HAM/TSP patients and asymptomatic carriers.
Whole cohort
(N=202, 230)
Excluding A*02 &
B*54 (N=84,116)
Metaserver A alleles 0.006 0.81
B alleles 0.001 0.01
Combined 0.0005 0.04
Epipred A alleles 0.0009 0.72
B alleles 0.0002 0.001
Combined 0.000001 0.006
The first column gives the P values of the Wilcoxon-Mann-Whitney tests for the
A and B loci. The second column repeats this analysis excluding individuals with
alleles from either the A*02 or B*54 allele families.
doi:10.1371/journal.ppat.1001117.t001
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response. Secondly, the fact that across all alleles and across all
proteins, peptide binding associated with immune control (reduced
proviral load) is strongly correlated with prevention of HAM/TSP
is the strongest evidence yet that the CD8
+ T cell response can
have a beneficial role in HTLV-1 infection.
The prevented fraction of disease, FP
We calculated the prevented fraction of disease attributable to
the possession of one or more strong binding alleles to HBZ [3]
(Methods). This showed that the possession of strong HBZ-
binding HLA alleles prevented (Fp)<48% (12.3% SD) of
potential cases of HAM/TSP in the study population. However,
although we found that a high proportion of potential HAM/
TSP cases are prevented by strong HBZ binding, it should be
noted that the strength of HBZ binding is not the only
determinant of disease status: in a logistic regression model,
the strength of HBZ binding alone could only correctly classify
55% of cases of HAM/TSP.
HBZ-specific CD8
+ T cells can be detected ex vivo
These results strongly imply that HBZ-specific CD8
+ T cells
play a protective role in HTLV-1 infection. HBZ immunogenic-
ity has been studied in ATL patients [35,36] but it is unknown
whether a HBZ-specific CD8
+ T cell response is generated or
even whether HBZ protein is expressed in asymptomatic carriers
and HAM/TSP patients. We therefore sought to identify HBZ-
specific CD8
+ T cells in fresh PBMCs from HTLV-1 infected
individuals. We assayed IFN-c production by ELISpot following
stimulation in vitro with a pool of overlapping peptides that
spanned the entire HBZ protein. Of 45 subjects tested, 31% had
detectable HBZ-specific CD8
+ T cells (Fig. 6). An independent
CD8
+ T cell assay, (CD107a mobilisation), confirmed that HBZ-
specific CD8
+ T cells are present in PBMC from infected
individuals. We conclude that HBZ protein is expressed in vivo
and is immunogenic.
Naturally infected cells can be lysed by an HBZ-specific
CD8
+ T cell clone
Recently, Sumeori et al established an HBZ-specific CD8
+ T
cell clone that recognised HBZ26–34 (GLLSLEEEL) in the context
of HLA-A*0201 [37]. They showed that this clone was able to lyse
an autologous B-lymphoblastoid cell line (B-LCL) that had been
loaded with HBZ peptide but that cells from an ATL patient were
resistant to killing. We investigated whether the same CD8
+ T cell
clone was able to kill naturally-infected cells from non-leukemic
HTLV-I-infected individuals. First we confirmed the finding of
Sumeori et al that autologous B-LCL loaded with HBZ26–34
peptide could be lysed by the CD8
+ T cell clone (data not shown).
Then we demonstrated, by a classical chromium release assay, that
naturally-infected CD4
+CD25
+ cells from the PBMCs of 3 out of 4
HLA-A*0201
+ non-leukemic patients were lysed by the CD8
+ T
cell clone but that cells from 3 out of 3 HLA-mismatched donors
were not lysed (Fig. 7). We conclude that naturally-infected cells
from AC and HAM/TSP patients are susceptible to lysis by an
HBZ-specific clone.
The comparative immunogenicity of HBZ and Tax
How does the immunogenicity of HBZ compare to Tax? We
compared the predicted top binding peptide from HBZ and Tax
respectively to 43 HLA class I alleles (the maximum capacity of
Metaserver). Peptides from Tax were predicted to bind signifi-
cantly more strongly than peptides from HBZ (P=0.00002, paired
Wilcoxon-Mann-Whitney; Fig. 8A). Consistent with this predic-
tion, the frequency of Tax-specific CD8
+ T cells by IFN-c
ELISpot was also significantly greater compared to HBZ CD8
+ T
cells in 45 HTLV-1-infected individuals (P=0.000006, paired
Wilcoxon-Mann-Whitney; Fig. 8B).
Discussion
We show that strong predicted binding of peptides from the
HTLV-1 protein HBZ is associated with a reduced risk of HAM/
Figure 4. The count of strong binding alleles to HBZ per individual against their proviral load in AC and HAM/TSP groups. The
number of HLA class I alleles that are strong binders to HBZ is significantly negatively correlated with proviral load (P=0.016). This analysis was
performed separately in HAM/TSP patients and ACs so it does not follow trivially from our previous observation that ACs (who have lower proviral
load than HAM/TSP patients) show stronger binding to HBZ.
doi:10.1371/journal.ppat.1001117.g004
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HTLV-1 infection in southern Japan. We demonstrated that
protection is not limited to a small subset of HLA class I alleles
previously associated with disease status and proviral load (HLA-
A*02 and HLA-Cw*08), but is generally associated with HLA class
I alleles that bind strongly to HBZ. Given that a protein-specific
HLA-restricted association is more likely to be mediated by CD8
+
T cells than NK cells which show limited protein specificity we
interpret this work in the context of the CD8
+ T cell response.
Prior to this analysis, CD8
+ T cells specific for the HTLV-1
protein Tax were often considered as the best candidate for
‘efficient’ or ‘protective’ CD8
+ cells because of the immunodomi-
nance of Tax in the CD8
+ T cell response [9,24]. Our finding that
binding of HBZ peptides rather than Tax peptides is protective
raises the question: why is HBZ a critical target for the immune
response?
HBZ functions by binding to cellular factors of the JUN and
ATF/CREB families [37]. There are two major splice variants of
theHBZtranscript, SP1and SP2; the variant SP1is more abundant
and isthevariantused inthis study[38,39]. Theabundance ofHBZ
transcript has been previously correlated with disease severity [39].
Expression of HBZ suppresses Tax-mediated transactivation
through the 59 LTR [20,40] and thereby inhibits expression of
other HTLV-1 genes [20,41]; HBZ can be expressed in the absence
of transcription of other HTLV-1 genes. Additionally, HBZ RNA
promotes the proliferation of infected T-lymphocytes [35]. This
dual action – reduction of HTLV-1 expression and subsequent
protection from immune surveillance, and enhancement of infected
cell proliferation – probably confers a survival advantage on HBZ-
expressing cells and is consistent with the observations that HBZ
enhances persistence in HTLV-1 inoculated rabbits [41] and that
ATL cells often have a hypermethylated or deleted 59 LTR but an
intact functional 39 LTR [35]. We hypothesise that if HBZ-specific
CD8
+ T cells are weak or absent then infected cells that express
HBZ but not other viral proteins will evade immune surveillance
and proliferate rapidly, leading to an increase in proviral load.
HBZ-specific CD8
+ T cells would then play an important role in
preventing this proliferation of provirus-positive cells and blocking
this strategy of persistence. If this conclusion is correct that CD8
+ T
cell recognition of HBZ plays a central role in the control of HTLV-
1 replication then one might expect that HBZ would have evolved
to minimize class I binding. Consistent with this hypothesis, we find
that the predicted binding affinity of HLA molecules to HBZ
peptides is significantly weaker than that of Tax peptides and that
the frequency of HBZ-specific CD8
+ T cells is significantly lower
than the frequency of Tax-specific CD8
+ T cells. Although the low
immunogenicity of HBZ is precisely what we predict given its
central importance in maintaining HTLV-1 persistence, it is
nevertheless striking that these low T cell frequency responses are
so important. This result challenges the prevailing assumption that
theimmunodominantresponse toa pathogen isthemost important.
We demonstrated using two different assays (IFNc ELISpot and
CD107 mobilisation) that HBZ-specific CTL are present in
PBMC from HAM/TSP patients and ACs. We further show that
naturally infected cells, isolated directly from HAM/TSP patients
and ACs, are susceptible to lysis by an HBZ-specific CTL clone.
Suemori et al have previously reported that the same HBZ-specific
CTL clone was unable to lyse leukemic cells isolated from a patient
with adult T cell leukemia [37]. The observation that aleukemic
but not leukemic cells can be lysed may be because leukemic cells
express lower levels of HLA: HBZ peptide on their surface or
because leukemic cells can be inherently harder to lyse [42–44].
This approach to studying the association between HLA class I
genotype and the outcome of infection has a number of strengths
compared with a traditional frequency-based analysis. Firstly, it is
more mechanistic: knowing that binding HBZ is associated with a
reduced proviral load and disease risk compared with knowing that
A*02 is associated with these outcomes is a simultaneously more
fundamental and more applicable level of understanding. Secondly,
identification of protective epitopes immediately suggests a practical
approach to measure and enhance, via therapeutic vaccination, the
efficiency of an individual’s anti-viral response. Thirdly, because the
same effect (e.g. HBZ binding) can be identified for many alleles it is
less likely to be a spurious result of linkage disequilibrium or genetic
stratification. Finally, effects due to multiple low-frequency alleles
can be captured because analysis is made at the level of peptide
binding rather than allelic frequency.
In summary, using a novel and generalizable approach, we have
identified one of the constituents of an effective CD8
+ T cell
response in HTLV-1 infection.
Methods
Subjects
Kagoshima cohort. Two hundred and thirty individuals
with HAM/TSP were compared with two hundred and two
randomly selected HTLV-1 seropositive asymptomatic carriers
(ACs) from the Kagoshima Red Cross Blood Transfusion Service.
All cases and controls were of Japanese ethnic origin and resided in
Kagoshima Prefecture, Japan. Full details of the cohort can be
found in [3]. Each individual was HLA class I typed using PCR–
sequence-specific primer reactions. Their proviral load in
Figure 5. HLA class I binding of peptides from different HTLV-1
proteins has a differential and correlated impact on both
proviral load and HAM/TSP risk. The HTLV-1 proteins were ranked
according to whether they were bound significantly more strongly by
asymptomatic carriers or HAM/TSP patients (x-axis; at the extremes ACs
were significantly more likely to bind peptides from HBZ, HAM/TSP
patients were significantly more likely to bind peptides from Env). This
list could be viewed as the ‘‘rank order of targets for a vaccine designed
to reduce HAM/TSP risk’’. Proteins were also ranked according to
whether binding their peptides was associated with a lower proviral
load (y-axis; at the extremes binding of HBZ was associated with a
significantly lower proviral load, binding of Env was associated with a
significantly higher proviral load). This list could be viewed as the ‘‘rank
order of targets for a vaccine designed to reduce proviral load’’. These
two sets of ranks were positively correlated (RS=0.86, P=0.0005,
Spearman’s rank correlation). That is, proteins whose peptides are
bound by asymptomatic carriers (left hand side of the graph) are,
independently, those associated with a lower proviral load when bound
(bottom of the graph).
doi:10.1371/journal.ppat.1001117.g005
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PCR.
St Mary’s cohort. IFNc ELISpot, CD107a mobilisation and
the chromium release assays were all carried out using cells from
HTLV-1-infected individuals attending St Mary’s Hospital.
Ethics statement: All subjects attended the National Centre
for Human Retrovirology at St. Mary’s Hospital and donated
blood after giving written informed consent as approved by the St.
Mary’s Hospital Research Ethics Committee.
Epitope prediction
We used two different algorithms to predict HLA class I
epitopes: Metaserver and Epipred. Figures based on Metaserver
predictions are in the main text, the corresponding figures for
Epipred are in Supporting Information S1.
Metaserver. Metaserver is a combination of two web-based
prediction methods that use artificial neural nets, NetCTL v1.2
[45] and NetMHC v3.0 [46,47]. NetCTL is an integrated method
that predicts TAP transport, proteasomal cleavage and HLA
binding for 12 different class I alleles. NetMHC v3.0 predicts
HLA-peptide binding for 43 HLA molecules. Metaserver
combines the two methods and removes a normalising
assumption (which held that all alleles bind the same number of
peptides) to produce a technique that shows improved accuracy in
epitope prediction [48] and predicts epitopes for 43 HLA
molecules.
Figure 6. HBZ-specific CD8
+ T cells are directly detectable ex vivo. (A) CD4-depleted PBMC from ACs and HAM/TSP patients produce IFNc in
response to HBZ peptide. CD4-depleted PBMC were cultured in the presence of HBZ peptide. After 6hrs IFNc producing cells were detected by ELISpot.
The threshold for a positive response to peptide was defined as greater than the mean plus two standard deviations of the number of spots in the
medium only control. (B) CD8
+ T cells from ACs and HAM/TSP patients degranulate in response to HBZ. PBMC were cultured in the presence of anti-
CD107a and monensin, in the presence of 2 mM HBZ peptide or its solvent, acetonitrile. After 5h, cells were harvested and stained. Dot plots shown
are gated on the CD3
+CD8
+ live population.
doi:10.1371/journal.ppat.1001117.g006
HLA Class I Binding in HTLV-1
PLoS Pathogens | www.plospathogens.org 7 September 2010 | Volume 6 | Issue 9 | e1001117Epipred. In order to validate our results, we used a second,
independent method of epitope prediction [49]. Epipred uses a
logistic regression model that is trained on all available data across
all HLA class I alleles and then specified for an individual allele.
Epitope prediction - allele coverage
Other than our initial comparison (protective against detrimen-
tal alleles), analysis was limited to A and B loci for two reasons:
Metaserver does not have algorithms for the C loci and C loci
Figure 7. Naturally infected cells from ACs and HAM/TSP patients are susceptible to lysis by an HBZ-specific A*0201-restricted
clone. Target CD4
+CD25
+ cells from four HLA-A*0201
+ and three HLA-A*0201
2 HTLV-I infected individuals were labelled with
51Chromium and mixed
with an HBZ-specific clone at the indicated effector:target ratios in triplicate. The cells were co-cultured for 4h, after which target lysis was detected
by chromium release into the supernatant. Only a small proportion of CD4
+CD25
+ cells will be infected so as well as expressing lysis as percentage of
total CD4
+CD25
+ cells lysed (primary, left hand y axis) we also estimated the proportion of provirus-positive cells lysed (secondary, right hand y axis).
We found that naturally infected targets were susceptible to lysis in 3 out of 4 HLA matched individuals (first column) but in 0 out of 3 HLA-
mismatched individuals (second column). Maximum lysis in the 3 responding individuals was in the range 10–30% of provirus-positive cells lysed in
4h. Proviral load in the 7 individuals is as follows: TAA 3.5, TBW 5.67, TAQ 3, TAC 10, HFE 6.27, TAL 9.1, TAN 4 copies per 100 PBMC.
doi:10.1371/journal.ppat.1001117.g007
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HLA-C experimental binding affinities to train the software.
Metaserver provided coverage of 84% of the total count of A/B
alleles in the Kagoshima cohort.
The missing alleles were: A*0207, A*0210, A*2603, A*3201,
B*1301, B*1501, B*1508, B*1511, B*1518, B*2704, B*3701,
B*3802, B*4005, B*4006, B*4601, B*4801, B*5201, B*5501,
B*5504, B*5601, B*5603, B*5605, B*5705, B*5901, and B*6701.
We were able to obtain predictions for [A*0207, A*0210],
A*2603 and [B*4005, B*4006] to a resolution of 2 digits by
combining the predictions of other A02*, A26* and B40*
predictors according to their frequency in Kagoshima.
Estimated number of epitope-allele combinations
We estimate that approximately 2,200 peptides could be bound
by the alleles present in the Kagoshima cohort. This figure is 1%
[45] of the 3,389 overlapping nonamers of the HTLV-1 proteome
multiplied by the number of unique alleles (65) in the cohort.
Prediction quality
The accuracy of epitope prediction algorithms has increased to
such an extent that the correlation between predicted binding
affinities and measured binding affinity is as strong as the correlations
of measurements between different laboratories [50]. The specificity
of epitope predictors has been tested by predicting a set of CTL
epitopes and subsequently verifying CD8
+ T cell responses against
these epitopes experimentally. Using this technique has yielded true-
positive (correctly predicted) estimates of 62–80% [51]. Using the
more direct approach of mass spectrometry to determine HLA-
peptide binding yielded a true positive rate of greater than 98% [52].
Additionally, we verified the prediction software we used (Metaserver
and Epipred) for HTLV-1 peptides.
The rank measure
Both prediction methods that we use produce a score for each
peptide-HLA that represents the binding strength of that complex.
In theory this score would allow us to compare predicted binding
affinities between alleles. However, between allele comparisons
can be problematic. Firstly, within-allele comparisons (i.e.
predictions for different peptides to the same allele) are thought
to be more comparable than predictions between alleles [45].
Secondly, whether or not a normalisation procedure should be
applied for between-allele comparisons is still being debated in the
community [48]. To avoid the potential problem of between-allele
comparisons we used the rank measure technique introduced by
Borghans et al. [53] in which she quantified the strength of
peptide-HLA class I binding for peptides from a particular protein
by ranking the binding score of peptides from the protein of
interest to the allele amongst the binding score of peptides from
the entire proteome to that allele; this approach has been
successfully applied in the context of HIV infection [25,28].
Specifically, we split each protein in the HTLV-1 reference
sequence into overlapping nonamers offset by a single amino acid.
Using the epitope prediction software, a predicted binding affinity
score was calculated for each of these peptides to each HLA allele
of interest. For each allele we ranked all nonamers from the
proteome from the strongest to weakest predicted binding scores.
This produced a list of rank values for each protein to that
particular allele that quantified the binding relationship between
that allele and the protein (an example is given in Table S4 in
Supporting Information S1). To check for robustness we also
repeated all calculations using an alternative to the rank measure:
the raw predicted affinity score. We found that our conclusions
were robust to the choice of method (Table S5 in Supporting
Information S1).
Independence of ranks
We were concerned that the binding of the top 8 peptides from
a protein to an allele may not be independent of one another.
Since, the strength of the strongest binder provides information
(i.e. an upper bound) about the strength of the second highest
binder. For this reason, apart from Fig. 2, only the top rank for
each protein-allele pair was used.
Figure 8. The comparative immunogenicity of HBZ and Tax. (A) The predicted top binding peptide from Tax and HBZ to each of the 43 alleles for
which Metaserver predicts binding affinities was found. Peptides from Tax are bound more strongly than peptides from HBZ (P=0.00002, paired Wilcoxon-
Mann-Whitney). Data pairs represent binding of the same allele to the two different proteins Tax and HBZ. (B) Consistent with this, the frequency of Tax-
specific CD8
+ T cells was also greater compared to HBZ-specific CD8
+ T cells in the 45 HTLV-1 infected individuals tested using IFN-c ELISpot (P=0.000006,
paired Wilcoxon-Mann-Whitney). Data pairs represent frequency of the response in the same individual to the two different proteins Tax and HBZ.
doi:10.1371/journal.ppat.1001117.g008
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binding
The REVEAL HLA-peptide binding assay (ProImmune Ltd.,
Oxford, UK) was used to quantify peptide-HLA binding. For each
allele-peptide combination that was tested, assembly of peptide-
HLA complexes was quantified by ELISA with a conformation-
dependent anti-HLA antibody. Samples of assembling peptide-
HLA complexes were taken at a defined time point and snap-
frozen in liquid nitrogen prior to analysis. The assembly for each
peptide-HLA complex was then compared against a positive
control peptide for that allele as the percentage of assembled
peptide relative to that control. We selected four HLA class I
alleles and 50 HTLV-1 peptides for each allele. The allele choice
was based on allele frequency in the Kagoshima database and
included 2 A alleles and 2 B alleles as well as alleles for which we
knew that the epitope prediction tended to be poor. The 50
HTLV-1 nonamer peptides for each allele were selected to
represent a range of predicted binding affinities, from weak to
strong binding peptides. They originated from 4 HTLV-1
reference strain proteins: Tax, HBZ, Gag and Polymerase.
Protective versus detrimental alleles
Due to allele coverage (see above), it was necessary to use
Metaserver for A*0201 and B*5401 and Epipred for Cw*0801. As
the rank values were derived for each allele separately, it was
acceptable to use different prediction methods for each allele in this
case. Epipred predicts binding to allele families rather than
individual alleles and so we calculated binding to Cw*08. The
ranks of the strongest binding 8 peptides from each protein to the
alleles A*0201 and Cw*08 (16 rank values) were compared against
the ranks of the strongest binding 8 peptides to the allele B*5401 (8
rank values). A Wilcoxon-Mann-Whitney test was performed for
each protein to test for differences between the two sets of rank
values. The analysis was repeated using top 5 and top 10 as well as
top 8 binding peptides, conclusions were robust to the choice of
number of peptides (Results in Supporting Information S1). Finally,
to avoid the potential problem of lack of independence of ranks (see
‘‘independence of ranks’’ above) we performed a binomial test on
the difference in strength of binding of A*02 and B*54 to HBZ
compared to all other HTLV-I proteins. The null hypothesis we
tested was ‘‘the difference in binding of detrimental and protective
alleles to HBZ is comparable to the other HTLV-1 proteins’’. For
each of the 12 HTLV-1 proteins we calculated the ranks of the
single highest ranking peptide from that protein to A*02 and B*54.
We then calculated the difference of these two ranks (detrimental –
beneficial) for each of the 12 proteins and asked, using the Binomial
test, whether the difference in binding for HBZ was larger than
would be expected under the null hypothesis.
HAM/TSP versus asymptomatic carriers
The analysis was carried out on each HTLV-1 protein in turn. For
each individual in the Kagoshima cohort, the rank of the top binding
peptide from the HTLV-1 protein to each of the individual’s A and B
HLA class I alleles was found (see The Rank Measure). These ranks
were then split into two groups – those from HAM/TSP patients and
those from asymptomatic carriers (AC). The two sets of ranks (HAM/
TSP vs. AC) were then compared for each protein using a Wilcoxon-
Mann-Whitney test (null hypothesis: HAM/TSP patients and
asymptomatic carriers bind the protein equally strongly).
Rank versus proviral load
We considered each HTLV-1 protein in turn. Firstly, we split
the cohort by disease status (AC or HAM/TSP). Then, for each
individual, we counted the number of alleles they possessed that
were strong binders to the protein of interest and then tested for
a correlation between the number of strong binders to the
protein and proviral load using the Spearman rank correlation.
A strong binding allele to a particularprotein was defined as one
that was in the top 40% of alleles. That is, the rank of the top
binding peptide from the HTLV-1 protein to each of the
individual’s A and B HLA class I alleles was found (see The
Rank Measure). This set of rank values (pooled HAM/TSP and
AC) was then ordered from highest to lowest rank and the alleles
that were represented in the top 40% of these ranks were
defined as strong binding alleles to that protein. Importantly,
for each protein, we looked at the relationship between strength
of binding and proviral load separately in HAM/TSP patients
a n dA C sa n dt h e nc o m b i n e dt h eP values using Fisher’s
combined test (rather than simply looking at the relationship in
the whole cohort). Therefore we could be confident that any
relationship between protein binding and proviral load that we
found did not follow trivially from a relationship between
protein binding and disease status and the fact that asymptom-
atic carriers have a significantly lower load than HAM/TSP
patients.
Our alternative metric for this method used the Rank Measure
to quantify the strength of binding of peptides from each HTLV-1
protein to each individual’s A and B alleles. We then tested for any
correlation between these values and the individuals’ proviral load
for HAM/TSP patients and asymptomatic carriers.
Robustness of conclusions
All analysis was performed with two independent epitope
prediction algorithms (Metaserver and Epipred) and with two
different methods (rank method, raw score method); additionally
an alternative approach to comparing protective v detrimental
alleles (based on the binomial test) and to comparing proviral load
with strength of binding were investigated. Conclusions were
highly robust (Table S5 in Supporting Information S1).
Statistical analysis
All statistical analysis was carried out using the R Project for
Statistical Computing [54]. The tests were non-parametric with
the exception of multiple linear regression. All P values reported
are 2-tailed. Fisher’s combined probability test was used to
combine P values.
Multivariate regression
General linear model analysis [55] was used to identify which
factors were predictors of proviral load, either in ACs or patients
with HAM/TSP.
Prevented fraction of disease, FP
To calculate the prevented fraction (Fp) of disease [3,56], we
used a 262 contingency table. The entries in the four cells were
as follows: a (HAM/TSP, positive for protective genotype)=183,
b (HAM/TSP, negative for protective genotype)=47, c (AC,
positive for protective genotype)=181, d (AC, negative for
protective genotype)=21. The fraction (Fp)o fp o t e n t i a lc a s e so f
HAM/TSP in the population that is prevented by the protective
genotype is given by Fp=(12R)6[12(d6r1/b6r2)], where
R=prevalence rate of HAM/TSP in the population (estimated
as 1% of the HTLV-1-infected population), r1=a+ba n d
r2=c+d. Fp is approximately normally distributed: the stan-
dard deviation is given by SD (Fp)=(12R2Fp)6![(c/d6r2)+(a/
b6r1)].
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+ T cells
Peripheral blood mononuclear cells (PBMC) were isolated from
whole blood from HTLV-1 infected individuals by density
gradient centrifugation.
IFNc ELISpot. PBMC were depleted of CD4
+ T cells using
MACS beads (Miltenyi Biotec). The resulting cells were cultured
in duplicate at a density of 100,000 cells per well in the presence of
a range of concentrations of pooled overlapping 20mer peptides
(offset by 6 amino acids) spanning HBZ, Tax, or with medium
alone. After 6 hours, IFN-c producing cells were detected by
ELISpot (Mabtech). The threshold for a positive response to
peptide was defined as greater than the mean plus two standard
deviations of the number of spots in the medium only control.
CD107 mobilisation assay. 1610
6 PBMC were cultured in
a 400 ml volume in the presence of 5 ml anti-CD107a-PE
(eBioscience, CA) 1.4 mg/ml monensin (eBioscience), 20 mg/ml
DNase (Sigma Aldrich, UK) with 2 mM HBZ peptide pool
(Mimotopes, Australia), or the equivalent volume of peptide
solvent, acetonitrile. After 5h, the cells were harvested and stained
for 30 min with Live/Dead red (Invitrogen,CA), a fixable viability
stain. Cells were fixed and permeablised using ebioscience FoxP3
staining buffer set according to the manufacturer’s instructions,
then stained with anti-CD3-APC-eFluor780, anti-CD4-eFluor450,
anti-CD8-PECy5 (all eBioscience) anti-IFN-c-FITC, anti-CD14-
ECD, anti-CD19-ECD (all Beckman Coulter, France). Samples
analysed by flow cytometry using a Cyan ADP (Beckman Coulter),
and summit software (DAKO). Doublets, dead cells, monocytes
and B cells were excluded from the analysis on the basis of forward
and side scatter, pulse width, viability staining, and CD14 or
CD19 expression. Antigen-specific CD8
+ T cells were identified as
CD3
+CD8
+ cells capable of producing IFN-c and/or mobilising
CD107 to the cell surface.
CD8
+ lysis assay: chromium release
PBMC from HLA A*0201
+ and HLA A*0201
2 HTLV-1
infected individuals were depleted of CD8
+ cells, then enriched
for CD25
+ cells using MACS beads (Miltenyi Biotech, Germany),
according to manufacturer’s instructions. CD25
+ cells were
cultured for 16h to allow for viral antigen expression and
presentation, then labelled with
51Cr by incubating for 1h in the
presence of 50–100 mCi Na2CrO4 (MP Biomedicals, USA).
Labelled cells were washed extensively and placed in culture in
triplicate (40,000 cells/well) in the presence of defined ratios of
HBZ-1, a CTL clone which recognises HBZ 26–34 in the context
of HLA A*0201 [37], alone or in the presence of 5% Triton x-100
(Sigma Aldrich). As a control,
51Cr labelled B-LCL (autologous to
the CTL clone) were cultured at the same ratios, with and without
1 mM HBZ 26–34 peptide. After 4h, culture supernatants were
harvested, placed on a scintillation plate, and
51Cr release was
assayed using a beta counter. Total specific lysis was calculated
using the following formula: [chromium release (test well)2
chromium release (no CTL control)]/ [chromium release
(Triton2100% lysis)2chromium release (no CTL control)]*100,
expressed as a percentage specific lysis of total cells. As not all
CD4
+CD25
+T cells are infected, and thus do not represent targets
for the CTL line, an estimate of specific lysis of infected cells was
also calculated, making the conservative assumption that all the
viral load is present in CD25
+ cells, [57], and that the CTL line
only kills infected cells. Percentage infected cells lysed was
calculated using the following formula: [Percentage total cells
lysed]/[fraction of CD4
+CD25
+ cells that are infected i.e. provirus
positive].
HTLV-1 proteome
The reference strain is from [58], with the exception of HBZ,
which was identified more recently and described in [35]
(Supporting Information S1: HTLV-1 reference strain).
Supporting Information
Supporting Information S1 Supporting information
Found at: doi:10.1371/journal.ppat.1001117.s001 (0.78 MB
DOC)
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